Geode Capital Management LLC Purchases 3,710 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Geode Capital Management LLC increased its holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,137 shares of the company’s stock after acquiring an additional 3,710 shares during the period. Geode Capital Management LLC owned about 0.67% of TriSalus Life Sciences worth $1,023,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC purchased a new position in TriSalus Life Sciences in the third quarter worth $92,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Insider Activity

In related news, CFO James Emmett Young acquired 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were acquired at an average price of $5.65 per share, with a total value of $33,900.00. Following the acquisition, the chief financial officer now owns 30,000 shares of the company’s stock, valued at approximately $169,500. This trade represents a 25.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 32.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TLSI. Lake Street Capital assumed coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 target price for the company. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Buy” and an average target price of $11.56.

TriSalus Life Sciences Stock Down 0.8 %

Shares of NASDAQ:TLSI opened at $5.09 on Friday. The company has a 50-day moving average price of $5.49 and a two-hundred day moving average price of $4.92. TriSalus Life Sciences, Inc. has a twelve month low of $3.50 and a twelve month high of $10.24. The firm has a market capitalization of $164.26 million, a PE ratio of -2.04 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $8.26 million during the quarter, compared to the consensus estimate of $8.12 million. Analysts anticipate that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.